Vineet Laboratories Limited Stock Price Today (NSE: VINEETLAB)
Fundamental Score
Vineet Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vineet Laboratories Limited share price today is ₹35.89, up +0.79% on NSE/BSE as of 16 September 2026. Vineet Laboratories Limited (VINEETLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹33.09 (Cr). The 52-week high for VINEETLAB share price is ₹49.99 and the 52-week low is ₹27.96. The company has a Return on Equity (ROE) of -89.47% and a debt-to-equity ratio of 2.73.
Vineet Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Vineet Laboratories Limited share price chart: 0.39% return over the past month. 52-week high ₹49.99, 52-week low ₹27.96.
Vineet Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹35.61 | ₹35.99 | ₹34.41 | ₹35.89 | 82.55K (Cr) | |
| ₹35.17 | ₹36.50 | ₹35.17 | ₹35.61 | 1.64L (Cr) | |
| ₹37.09 | ₹37.57 | ₹35.01 | ₹37.02 | 71.65K (Cr) | |
| ₹37.14 | ₹37.65 | ₹35.50 | ₹35.79 | 61.16K (Cr) | |
| ₹37.90 | ₹38.78 | ₹36.88 | ₹37.14 | 73.02K (Cr) | |
| ₹37.90 | ₹38.30 | ₹35.66 | ₹36.94 | 36.33K (Cr) | |
| ₹37.90 | ₹38.30 | ₹37.17 | ₹37.28 | 70.77K (Cr) | |
| ₹37.70 | ₹38.29 | ₹36.82 | ₹37.37 | 38.38K (Cr) | |
| ₹37.89 | ₹38.69 | ₹37.10 | ₹37.50 | 49.88K (Cr) | |
| ₹38.95 | ₹38.95 | ₹36.31 | ₹37.57 | 67.67K (Cr) |
Vineet Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹39.00 | ₹39.00 | ₹34.41 | ₹35.89 | -7.97% | |
| ₹40.00 | ₹40.00 | ₹35.01 | ₹38.86 | -2.85% | |
| ₹34.14 | ₹40.20 | ₹31.50 | ₹39.63 | +16.08% | |
| ₹34.40 | ₹35.79 | ₹32.50 | ₹33.81 | -1.72% | |
| ₹38.06 | ₹40.99 | ₹32.76 | ₹33.97 | -10.75% | |
| ₹31.60 | ₹43.50 | ₹28.66 | ₹38.06 | +20.44% | |
| ₹29.50 | ₹32.69 | ₹27.96 | ₹29.06 | -1.49% | |
| ₹34.45 | ₹35.40 | ₹28.75 | ₹29.53 | -14.28% | |
| ₹36.01 | ₹36.50 | ₹30.24 | ₹32.78 | -8.97% | |
| ₹42.67 | ₹44.60 | ₹35.60 | ₹36.78 | -13.80% | |
| ₹46.79 | ₹49.44 | ₹39.52 | ₹41.85 | -10.56% | |
| ₹38.65 | ₹49.99 | ₹37.55 | ₹46.50 | +20.31% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vineet Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vineet Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VINEETLAB across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
11 factors identified
Below-Average Return on Equity (-89.47%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-27.95%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.28%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-108.80%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-74.31%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 2.73)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-4.22x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.91)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Low Promoter Commitment (15.89%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.36%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vineet Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vineet Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vineet Laboratories LimitedVineet Laborato...Selected✓ VINEETLAB • 543298 | 3/100 | ₹35.89₹36 | ₹33.09₹33.09 | — — | -89.47%Poor -89.47% Poor | -27.95%Poor -27.95% Poor | 2.73Poor 2.7 Poor | — — | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Vineet Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for VINEETLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.11 | ₹59.14 | 53.3x |
| FY 2023 | ₹1.36 | ₹81.65 | 60x |
| FY 2022 | ₹7.16 | ₹63.25 | 8.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vineet Laboratories Limited Dividend History
Annual cash dividends paid by VINEETLAB — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹0.92 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Vineet Laboratories Limited Quarterly Performance
Latest quarterly metrics for VINEETLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-74.31%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-108.80%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Vineet Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VINEETLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vineet Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Vineet Laboratories Limited (VINEETLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Vineet Laboratories Limited
About VINEETLAB (Vineet Laboratories Limited)
Vineet Laboratories Ltd is a dynamic force within the pharmaceutical landscape, dedicated to the meticulous crafting of high-quality active pharmaceutical ingredients, specialty in...termediates, and a diverse portfolio of fine chemicals. From its state-of-the-art facilities, the company pioneers innovative methodologies and rigorous quality control protocols, ensuring that each product meets the stringent demands of both domestic and international markets. Their unwavering commitment to scientific excellence and process optimization positions them as a trusted partner for pharmaceutical companies seeking reliable and efficacious raw materials, driving advancements in drug development and patient care. Focusing on the intricate building blocks of modern medicine, Vineet Laboratories specializes in the production of key intermediates for a range of crucial APIs, including those utilized in antiviral therapies and treatments for chronic conditions. Through continuous research and development, they expand their product offerings, adapting to the evolving needs of the pharmaceutical industry. Vineet Laboratories also expertly formulates fine chemicals and reagents, catering to specialized scientific applications and supporting researchers across various disciplines. The company's dedication to precision and purity ensures that these critical compounds contribute significantly to scientific progress. Vineet Laboratories takes pride in its commitment to sustainable manufacturing practices. They prioritize environmental responsibility by implementing innovative technologies that minimize waste and optimize resource utilization. With a focus on customer satisfaction, they offer personalized solutions, ensuring that their clients receive the specific compounds they need, precisely when they need them. Vineet Laboratories fosters long-term relationships with its partners, contributing to the advancement of global healthcare by delivering reliable and consistent products.
Company Details
Key Leadership
VINEETLAB Share Price: Frequently Asked Questions
What is the current share price of Vineet Laboratories Limited?
Vineet Laboratories Limited (VINEETLAB) trades at ₹35.89 on NSE and BSE. Market cap ₹33.09 (Cr). Educational data only.
What is the P/E ratio of Vineet Laboratories Limited?
Vineet Laboratories Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Vineet Laboratories Limited?
Vineet Laboratories Limited has a Bull Run score of 3/100 based on 25+ financial parameters.
Does Vineet Laboratories Limited pay dividends?
Vineet Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vineet Laboratories Limited?
Vineet Laboratories Limited has ROE of -89.47%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vineet Laboratories Limited?
Vineet Laboratories Limited has debt-to-equity of 2.73.
Is Vineet Laboratories Limited a good investment?
Bull Run gives Vineet Laboratories Limited a score of 3/100. This is not investment advice — consult a SEBI-registered advisor.